EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Exploring the role of chemerin in skeletal muscle phenotype in those with kidney disease

Luke A Baker, Thomas J Wilkinson, Amelia Rmj Abbott, Daniela F Cardoso, Nicola Parker, Matthew J Denniff, Roseanne E Billany, Daniel S March, Hannah Ml Young, Patrick Highton, Matthew Pm Graham-Brown, Robert U Ashford und 4 weitere

Translational Research · 2026

DOI: 10.1016/j.trsl.2026.02.009 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Translational Research, 2026. Verfasst von Luke A Baker und 15 weiteren Autor:innen. Beteiligte Einrichtung: Division of Respiratory Sciences, University of Leicester, Leicester, UK; Leicester Biomedical Research Centre (BRC), Leicester Diabetes Centre, Univ…. Hauptthemen laut MEDLINE: Chemokines, Muscle, Skeletal, Renal Insufficiency, Chronic, Intercellular Signaling Peptides and Proteins. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Kidney Research UK.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

INTRODUCTION: People with chronic kidney disease (CKD) often experience poor muscle quality and elevations in skeletal muscle wasting and dysfunction, contributing to a reduced quality of life and an increased risk of morbidity and mortality. The adipokine chemerin is associated with CKD progression and is involved in inflammatory-related signalling processes. With chronic inflammation recognised as a driving factor in uraemic sarcopenia, we aimed to investigate the potential role of chemerin as a uraemic toxin in CKD and identify the mechanisms of action to elucidate therapeutic opportunities in uraemic sarcopenia. METHODS: To achieve this, we used a holistic approach utilising in-vivo, ex-vivo and in-vitro analyses in order to explore the link between chemerin and skeletal muscle in the context of CKD. Chemerin levels from EDTA-plasma and urine samples were quantified via ELISA on basal samples from those across the kidney disease continuum. Chemerin levels were correlated with eGFR and measures of body composition, physical performance, muscle mass, and muscle quality. A sub-set of participants from each group underwent skeletal muscle biopsies, and samples were processed for gene and protein analysis, or cells extracted for in-vitro experimentation. For in-vitro experiments, human-derived muscle cells (HDMCs) isolated from CKD or aged-matched controls (CON) were differentiated and subsequently exposed to a dose-response of Chemerin. Subsequent experiments used the CMKLR1 selective inhibitor to seek to identify a mechanism of action. RESULTS: Higher circulating chemerin was associated with lower eGFR (R2 = 0.3262, p < 0.001). Positive correlations with body fat % and BMI were noted in CKD patients. Higher circulatory chemerin was associated with poorer muscle quality (R2 = 0.043, p = 0.057). The expression of Chemerin and its proposed receptor of interest CMKLR1 was detected in skeletal muscle. In-vitro analysis showed that the exposure of CKD-derived muscle cells to chemerin induced a significant inflammatory response (IL-6 p < 0.001; CCL-2 p = 0.0215), which was halved using the CMKLR1 receptor inhibitor αNETA (IL-6 p < 0.001; CCL-2 p < 0.001). CONCLUSION: We report that chemerin is a uraemic toxin in those with CKD and may contribute to poorer muscle quality in these people. Chemerin can moderate indicators of inflammation within HDMCs via the activation of CMKLR1 and warrants further investigations to validate it as a potential new therapeutic target to alleviate the symptoms of uraemic sarcopenia.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ChemokinesMuscle, SkeletalRenal Insufficiency, ChronicIntercellular Signaling Peptides and ProteinsHumansFemaleMalePhenotypeMiddle AgedAgedReceptors, Chemokine

Stichwörter der Autor:innen

ChemerinChronic Kidney DiseaseInflammationMuscle qualityPhysical functionSkeletal muscle

Substanzen

ChemokinesRARRES2 protein, humanIntercellular Signaling Peptides and ProteinsCMKLR1 protein, humanReceptors, Chemokine

Autor:innen und Institutionen

  • Division of Respiratory Sciences, University of Leicester, Leicester, UK; Leicester Biomedical Research Centre (BRC), Leicester Diabetes Centre, University of Leicester, Leicester, UK. Electronic address: luke.baker@lei…
  • Leicester Biomedical Research Centre (BRC), Leicester Diabetes Centre, University of Leicester, Leicester, UK.
  • Division of Respiratory Sciences, University of Leicester, Leicester, UK.
  • Research Centre in Sports Sciences, Health Sciences and Human Development, CIDESD, University of Maia, Portugal.
  • Division of Cardiovascular Sciences, University of Leicester, Leicester, UK.
  • National Institute for Health and Care Research Applied Research Collaboration (ARC) East Midlands, University of Leicester, Leicester, UK.

Förderung

  • Kidney Research UK

Zitieren

APA

Baker, L. A., Wilkinson, T. J., Abbott, A. R., Cardoso, D. F., Parker, N., Denniff, M. J., Billany, R. E., March, D. S., Young, H. M., Highton, P., Graham-Brown, M. P., Ashford, R. U., Viana, J. L., Burton, J. O., Smith, A. C., & Watson, E. L. (2026). Exploring the role of chemerin in skeletal muscle phenotype in those with kidney disease. Translational Research. https://doi.org/10.1016/j.trsl.2026.02.009

Vancouver

Baker LA, Wilkinson TJ, Abbott AR, Cardoso DF, Parker N, Denniff MJ, et al. Exploring the role of chemerin in skeletal muscle phenotype in those with kidney disease. Translational Research. 2026. doi:10.1016/j.trsl.2026.02.009

BibTeX
@article{Baker2026,
  author = {Baker, Luke A and Wilkinson, Thomas J and Abbott, Amelia Rmj and Cardoso, Daniela F and Parker, Nicola and Denniff, Matthew J and Billany, Roseanne E and March, Daniel S and Young, Hannah Ml and Highton, Patrick and Graham-Brown, Matthew Pm and Ashford, Robert U and Viana, João L and Burton, James O and Smith, Alice C and Watson, Emma L},
  title = {Exploring the role of chemerin in skeletal muscle phenotype in those with kidney disease},
  journal = {Translational Research},
  year = {2026},
  doi = {10.1016/j.trsl.2026.02.009}
}
Kostenlos starten →